July 24, 2021

Ukraine Breaking News

Ukraine Breaking News | The Latest News In Ukraine

After doses of the COVID-19 vaccine, how long does the protection last?

After doses of the COVID-19 vaccine, how long does the protection last?

In the United States, the number of adults who have received at least one dose of a COVID-19 vaccine is now higher than the number who have not. Additionally, one in three US adults are now fully vaccinated, according to data from the Centers for Disease Control and Prevention.

With so many Americans being immunized and millions of others joining them every day, it’s only natural to look ahead and wonder how long this protection will last.

The answer is as simple as it is unsatisfactory: no one knows.

“We still don’t know how long the vaccine immunity we have on hand right now,” said Dr. Katherine O’Brien, who heads the vaccine department at the World Health Organization, in a podcast. “We will really have to wait for the time to pass to see how long these vaccines last.”

The first two vaccines cleared by the Food and Drug Administration – one manufactured by Pfizer and BioNTech, the other manufactured by Moderna – began going into the arms at the end of July as part of their Phase 3 clinical trials. three weeks later in the Pfizer-BioNTech trial and four weeks later in Moderna.

After the second dose, it takes another two weeks for the immune system to achieve full protection. This means that the first people to be fully immunized reached that milestone in September, about six months ago.

Vaccine makers are tracking these clinical trial volunteers and testing them to see if the benefits of their shots have held steady or have begun to decline. So far, they both look strong.

As of April 1, the number of people who had been out of their second dose of Pfizer-BioNTech vaccine for at least six months had jumped to 12,000, and they are still seeing “high vaccine efficacy,” according to Albert Bourla, chief executive of the company. Pfizer.

Among all trial participants, the vaccine was 91.3 percent effective in preventing COVID-19 cases through March 13, Pfizer and BioNTech said in a statement. This figure increased to 92.6% for participants from the United States. Additionally, the vaccine was at least 95.3% effective in preventing severe COVID-19 cases.